We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lipid Disorders in NAFLD and Chronic Kidney Disease.
- Authors
Yang, Meng; Geng, Chang-An; Liu, Xinguang; Guan, Min
- Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver dysfunction and is characterized by exaggerated lipid accumulation, inflammation and even fibrosis. It has been shown that NAFLD increases the risk of other chronic diseases, particularly chronic kidney disease (CKD). Lipid in excess could lead to liver and kidney lesions and even end-stage disease through diverse pathways. Dysregulation of lipid uptake, oxidation or de novo lipogenesis contributes to the toxic effects of ectopic lipids which promotes the development and progression of NAFLD and CKD via triggering oxidative stress, apoptosis, pro-inflammatory and profibrotic responses. Importantly, dyslipidemia and release of pro-inflammatory cytokines caused by NAFLD (specifically, nonalcoholic steatohepatitis) are considered to play important roles in the pathological progression of CKD. Growing evidence of similarities between the pathogenic mechanisms of NAFLD and those of CKD has attracted attention and urged researchers to discover their common therapeutic targets. Here, we summarize the current understanding of molecular aberrations underlying the lipid metabolism of NAFLD and CKD and clinical evidence that suggests the relevance of these pathways in humans. This review also highlights the orchestrated inter-organ cross-talk in lipid disorders, as well as therapeutic options and opportunities to counteract NAFLD and CKD.
- Subjects
FATTY liver; CHRONIC kidney failure; NON-alcoholic fatty liver disease; FIBROSIS; DRUG target; LIPID metabolism; LIPIDS
- Publication
Biomedicines, 2021, Vol 9, Issue 10, p1405
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines9101405